Retinoid receptor-dependent and independent biological activities of novel fenretinide analogues and metabolites.
暂无分享,去创建一个
V. Steele | A. Sabichi | R. Lotan | J. Clifford | G. Kelloff | Xiulan Yang | Hui Xu | S. Fischer | C. Zou
[1] P. Chambon,et al. F9 embryocarcinoma cells: a cell autonomous model to study the functional selectivity of RARs and RXRs in retinoid signaling. , 2001, Histology and histopathology.
[2] V. Steele,et al. Identification of retinamides that are more potent than N-(4-hydroxyphenyl)retinamide in inhibiting growth and inducing apoptosis of human head and neck and lung cancer cells. , 2001, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[3] V. Steele,et al. Effects of novel phenylretinamides on cell growth and apoptosis in bladder cancer. , 2001, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[4] B. Casto,et al. Differential response of normal, premalignant and malignant human oral epithelial cells to growth inhibition by chemopreventive agents. , 2000, Anticancer research.
[5] M. Sporn,et al. Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer. , 1999, Journal of the National Cancer Institute.
[6] S. Kitareewan,et al. 4HPR triggers apoptosis but not differentiation in retinoid sensitive and resistant human embryonal carcinoma cells through an RARγ independent pathway , 1999, Oncogene.
[7] A. Sabichi,et al. Cancer chemoprevention: progress and promise. , 1998, Journal of the National Cancer Institute.
[8] R. Mehta,et al. Metabolism of N-[4-hydroxyphenyl]retinamide (4-HPR) to N-[4-methoxyphenyl]retinamide (4-MPR) may serve as a biomarker for its efficacy against human breast cancer and melanoma cells. , 1998, European journal of cancer.
[9] A. Sabichi,et al. Retinoic acid receptor beta expression and growth inhibition of gynecologic cancer cells by the synthetic retinoid N-(4-hydroxyphenyl) retinamide. , 1998, Journal of the National Cancer Institute.
[10] P. Chambon,et al. Specific and Redundant Functions of Retinoid X Receptor/Retinoic Acid Receptor Heterodimers in Differentiation, Proliferation, and Apoptosis of F9 Embryonal Carcinoma Cells , 1997, The Journal of cell biology.
[11] E. Dmitrovsky. N-(4-hydroxyphenyl)retinamide activation of a distinct pathway signaling apoptosis. , 1997, Journal of the National Cancer Institute.
[12] P. Chambon,et al. Distinct retinoid X receptor-retinoic acid receptor heterodimers are differentially involved in the control of expression of retinoid target genes in F9 embryonal carcinoma cells , 1997, Molecular and cellular biology.
[13] A. Fanjul,et al. 4-Hydroxyphenyl Retinamide Is a Highly Selective Activator of Retinoid Receptors* , 1996, The Journal of Biological Chemistry.
[14] P. Chambon,et al. RXRalpha‐null F9 embryonal carcinoma cells are resistant to the differentiation, anti‐proliferative and apoptotic effects of retinoids. , 1996, The EMBO journal.
[15] P. Chambon. A decade of molecular biology of retinoic acid receptors , 1996, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[16] R. Lotan,et al. Differential induction of apoptosis by all-trans-retinoic acid and N-(4-hydroxyphenyl)retinamide in human head and neck squamous cell carcinoma cell lines. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.
[17] C. Lau,et al. Comparison of N-(4-hydroxyphenyl)retinamide and all-trans-retinoic acid in the regulation of retinoid receptor-mediated gene expression in human breast cancer cell lines. , 1996, Cancer research.
[18] R. Evans,et al. The RXR heterodimers and orphan receptors , 1995, Cell.
[19] D. Hill,et al. N-(4-hydroxyphenyl)retinamide: interactions with retinoid-binding proteins/receptors. , 1995, Carcinogenesis.
[20] B. Conley,et al. N-(4-hydroxyphenyl)retinamide (4-HPR)-mediated biological actions involve retinoid receptor-independent pathways in human breast carcinoma. , 1995, Carcinogenesis.
[21] S. Lippman,et al. Randomized placebo-controlled trial of isotretinoin in chemoprevention of bronchial squamous metaplasia. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] U. Veronesi,et al. Prospects of chemoprevention of human cancers with the synthetic retinoid fenretinide. , 1994, Cancer research.
[23] S. Ménard,et al. N-(4-hydroxyphenyl)retinamide induces apoptosis of malignant hemopoietic cell lines including those unresponsive to retinoic acid. , 1993, Cancer research.
[24] P. Chambon,et al. Loss of retinoic acid receptor gamma function in F9 cells by gene disruption results in aberrant Hoxa-1 expression and differentiation upon retinoic acid treatment. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[25] M. Clerici,et al. Five-year administration of fenretinide: pharmacokinetics and effects on plasma retinol concentrations. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] M. Sporn,et al. Progress and Perspectives in Chemoprevention of Cancer , 1992 .
[27] W. Bursch,et al. Determination of the length of the histological stages of apoptosis in normal liver and in altered hepatic foci of rats. , 1990, Carcinogenesis.
[28] R. Moon,et al. N-(4-hydroxyphenyl)-all-trans-retinamide pharmacokinetics in female rats and mice. , 1986, Drug metabolism and disposition: the biological fate of chemicals.
[29] T. Mosmann. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. , 1983, Journal of immunological methods.
[30] L. Gudas,et al. Isolation of cDNA clones specific for collagen IV and laminin from mouse teratocarcinoma cells. , 1983, Proceedings of the National Academy of Sciences of the United States of America.
[31] R. Lotan,et al. Relationships among retinoid structure, inhibition of growth, and cellular retinoic acid-binding protein in cultured S91 melanoma cells. , 1980, Cancer research.
[32] S. Lippman,et al. Retinoid receptor-dependent and -independent effects of N-(4-hydroxyphenyl)retinamide in F9 embryonal carcinoma cells. , 1999, Cancer research.
[33] H. Rui. Research and development of cancer chemopreventive agents in China , 1997, Journal of cellular biochemistry. Supplement.
[34] V. Steele,et al. Clinical development plan: N-(4-hydroxyphenyl)retinamide. , 1994, Journal of cellular biochemistry. Supplement.
[35] L. Mariani,et al. Fenretinide (4‐HPR) in chemoprevention of oral leukoplakia , 1993, Journal of cellular biochemistry. Supplement.
[36] R. Mehta,et al. Distribution of fenretinide in the mammary gland of breast cancer patients. , 1991, European journal of cancer.